JNJ issues 2017 guidance, reports full-year Darzalex sales

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported mixed 4Q16 earnings and issued full-year 2017 guidance that fell short of analysts' consensus. The company also reported strong sales of multiple myeloma drug Darzalex daratumumab in its first full year on the market.

J&J expects adjusted EPS of $6.93-$7.08 on revenues of $74.1-$74.8 billion in 2017. Analysts had estimated adjusted EPS of $7.11 on $75.1 billion in revenue...